Search clinical trials for: TIGIT inhibitor

Total 67890 results

Omico
Hoffmann-La Roche; The George Institute for Global Health, Australia

Recruiting

Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients (MoST-TAP)

Solid Tumor, Adult

Australia
Arcus Biosciences, Inc.
Gilead Sciences

Recruiting

Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer (EDGE-Lung)

Advanced Non-Small Cell Lung Cancer

United States, Korea, Republic of, Australia, United Kingdom, Taiwan, Spain
Hoffmann-La Roche

Recruiting

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Urothelial Cancer

Korea, Republic of, United States, Brazil, China, France, Germany, Mexico, Poland, Denmark, Italy, Turkey, Australia, Greece, Spain, United Kingdom
M.D. Anderson Cancer Center

Recruiting

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

Metastatic Malignancy

United States
Arcus Biosciences, Inc.
Gilead Sciences

Recruiting

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)

Gastrointestinal Tract Malignancies

United States, Korea, Republic of, France, Serbia, Canada
Diwakar Davar
Arcus Biosciences, Inc.

Recruiting

Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

Melanoma

United States
iTeos Belgium SA
GlaxoSmithKline; iTeos Therapeutics

Recruiting

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors (TIG-006)

Melanoma | Head and Neck Cancer | Lung Cancer | Advanced Cancer

Spain, Italy, France, United States, United Kingdom, Belgium
Compugen Ltd

Recruiting

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Multiple Myeloma | Ovarian Cancer | Lung Cancer | Advanced Cancer | Colon Cancer | Plasma Cell Neoplasm | HNSCC | Microsatellite Stable Colorectal Carcinoma | MSS-CRC

United States
Merck Sharp & Dohme LLC

Recruiting

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

Melanoma

Spain, Poland, United States, Australia, France, Israel, Italy, South Africa, Switzerland, Chile, Greece, Colombia, Hungary, Argentina
GlaxoSmithKline
iTeos Belgium SA

Recruiting

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Neoplasms

United States, Italy, Spain, France, Germany, Canada, Korea, Republic of, Netherlands, Poland, Romania, Russian Federation, Sweden
BeiGene

Active, not recruiting

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

NSCLC | Non-small Cell Lung Cancer

United States
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

Melanoma

Poland, Australia, Canada, United States, Argentina, Austria, Belgium, Brazil, Chile, China, Colombia, France, Germany, India, Ireland, Israel, Italy, Japan, Korea, Republic of, New Zealand, South Africa, Spain, Sweden, Switzerland, Turkey and more
Pfizer

Active, not recruiting

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Carcinoma, Non-Small-Cell Lung

United States, Belgium, Taiwan, Australia, United Kingdom
BeiGene

Active, not recruiting

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Locally Advanced and Metastatic Solid Tumors

China, Taiwan, United States, Australia
Mereo BioPharma
ICON Clinical Research

Completed

A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors.

Advanced Solid Tumor | Metastatic Solid Tumor | Solid Tumor, Adult

United States, United Kingdom
Coherus Biosciences, Inc.
Shanghai Junshi Bioscience Co., Ltd.; Medpace, Inc.

Active, not recruiting

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Hepatocellular Carcinoma | Non-Small Cell Lung Cancer | Advanced Solid Tumor

United States
Compugen Ltd
Bristol-Myers Squibb

Active, not recruiting

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

Breast Cancer | Ovarian Cancer | Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Advanced Cancer | Colo-rectal Cancer | Ovarian Neoplasm | Neoplasm Malignant | Lung Neoplasm

United States
Compugen Ltd
Bristol-Myers Squibb

Active, not recruiting

COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.

Head and Neck Cancer | Ovarian Cancer | Solid Tumor | Endometrial Neoplasms

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

Melanoma

United States, Australia, France, Israel, Italy, Switzerland
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

Melanoma

United States, Australia, France, Israel, Italy, Switzerland
Multiple Myeloma Research Consortium
Bristol-Myers Squibb; Memorial Sloan Kettering Cancer Center; Washington University... and other collaborators

Active, not recruiting

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Multiple Myeloma | Relapsed Refractory Multiple Myeloma

United States
Novartis Pharmaceuticals

Withdrawn

Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer (AdvanTIG-211)

Triple Negative Breast Cancer
M.D. Anderson Cancer Center

Active, not recruiting

Etigilimab and Nivolumab for the Treatment of Platinum-Resistant Recurrent Clear Cell Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary Peritoneal Carcinoma | Recurrent Primary Peritoneal...

United States
OncoMed Pharmaceuticals, Inc.

Terminated

A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors

Metastatic Cancer | Locally Advanced Cancer

United States
West China Hospital

Not yet recruiting

Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma

Cholangiocarcinoma
Hoffmann-La Roche
Shanghai Roche Pharmaceutical Co., Ltd

Recruiting

Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)

Diabetic Macular Edema | Retinal Vein Occlusion | Neovascular Age-related Macular Degeneration

China
XIANG YANQUN

Not yet recruiting

Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial

Nasopharyngeal Carcinoma
National Cancer Institute (NCI)

Not yet recruiting

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

Metastatic Urothelial Carcinoma | Unresectable Urothelial Carcinoma
Tang-Du Hospital

Not yet recruiting

Baricitinib for the Lung Injury Following Spontaneous SAH (BLISS)

Spontaneous Subarachnoid Hemorrhage
M.D. Anderson Cancer Center
Incyte Corporation

Not yet recruiting

Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

Advanced Cholangiocarcinoma | FGFR2 Fusion

United States
EicOsis Human Health Inc.

Recruiting

Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury

Neuropathic Pain | Spinal Cord Injuries

United States
Mayo Clinic

Recruiting

Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial

Malignant Solid Neoplasm | Melanoma | Renal Cell Carcinoma | Lung Non-Small Cell Carcinoma | Urothelial Carcinoma | Lung Small Cell Carcinoma

United States
Dana-Farber Cancer Institute
Johns Hopkins University; Translational Breast Cancer Research Consortium

Not yet recruiting

The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Breast Cancer | HER2-positive Breast Cancer | Stage IV Breast Cancer | Breast Cancer Female | Breast Cancer Metastatic | Estrogen Receptor-positive Breast Cancer

United States
Zhejiang Cancer Hospital

Not yet recruiting

Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer

Gastric Cancer

China
Beijing Tongren Hospital
The First Affiliated Hospital with Nanjing Medical University

Not yet recruiting

Efficacy and Safety of Sugammadex in Thoracoscopy Thymectomy for Chinese Adults With Myasthenia Gravis

Reversal of Neuromuscular Blockade

China
Wuhan Union Hospital, China

Recruiting

Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis

Rhinitis, Allergic

China
First Affiliated Hospital of Zhejiang University
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Recruiting

Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML

Myeloid Malignancy | Relapsed/Refractory Acute Myeloid Leukaemia

China
Sun Yat-sen University

Recruiting

The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites

Malignant Ascites

China
Roswell Park Cancer Institute

Not yet recruiting

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Unresectable Triple-Negative Breast Carcinoma

United States
Hospital de Clinicas de Porto Alegre
Vifor Pharma

Not yet recruiting

IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency (COMBINED-HF)

Heart Failure, Systolic | Iron Deficiencies

Brazil
TC Erciyes University

Not yet recruiting

The Effect of Tranexamic Acid in Endoscopic and Microscopic Ear Surgery Cases on Surgeon Satisfaction

Middle Ear Disease
Massachusetts General Hospital
Patient-Centered Outcomes Research Institute

Not yet recruiting

Sequential Multiple Assignment Randomized Trial for Bipolar Depression (SMART-BD)

Depression | Bipolar I Disorder

United States, Canada
University of Dundee
Juvenile Diabetes Research Foundation; Lexicon Pharmaceuticals

Not yet recruiting

Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes (SOPHIST)

Heart Failure | Type 1 Diabetes
Chengdu Baiyu Pharmaceutical Co., Ltd.

Recruiting

A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors

Solid Tumor, Adult

China
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Stage IIIB | EGFR Gene Mutation | Non-small Cell Lung Cancer Stage IV
Cantonal Hospital Graubuenden
University of Zurich

Not yet recruiting

Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease (SIDIA)

Autosomal Dominant Polycystic Kidney Disease

Switzerland
Sun Yat-sen University

Not yet recruiting

Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer

Colorectal Cancer

China
JW Pharmaceutical

Not yet recruiting

PK,PD and DDI of Epaminurad and Naproxen in Healthy Volunteers

Healthy

Korea, Republic of
Johns Hopkins University

Recruiting

Opioid Use After Laparoscopic Salpingectomy

Opioid Use | Post-operative Pain | Sterility, Female

United States
Beijing Anzhen Hospital

Not yet recruiting

Efficacy of Dapagliflozin on Recurrence After Catheter Ablation for Atrial Fibrillation (DARE-AF)

Atrial Fibrillation

China

Search clinical trials for: TIGIT inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations